JP5495467B2 - 固形医薬組成物 - Google Patents

固形医薬組成物 Download PDF

Info

Publication number
JP5495467B2
JP5495467B2 JP2004111761A JP2004111761A JP5495467B2 JP 5495467 B2 JP5495467 B2 JP 5495467B2 JP 2004111761 A JP2004111761 A JP 2004111761A JP 2004111761 A JP2004111761 A JP 2004111761A JP 5495467 B2 JP5495467 B2 JP 5495467B2
Authority
JP
Japan
Prior art keywords
composition according
composition
alkyl
receptor agonist
carbon atoms
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP2004111761A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004307506A5 (OSRAM
JP2004307506A (ja
Inventor
朋幸 大村
プーディペッディ マデュスダーン
エドワード ロイス アラン
ルーガー コリーン
正喜 佐々木
徳裕 田村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Mitsubishi Tanabe Pharma Corp
Original Assignee
Mitsubishi Tanabe Pharma Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32326722&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP5495467(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Mitsubishi Tanabe Pharma Corp filed Critical Mitsubishi Tanabe Pharma Corp
Publication of JP2004307506A publication Critical patent/JP2004307506A/ja
Publication of JP2004307506A5 publication Critical patent/JP2004307506A5/ja
Application granted granted Critical
Publication of JP5495467B2 publication Critical patent/JP5495467B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/145—Amines having sulfur, e.g. thiurams (>N—C(S)—S—C(S)—N< and >N—C(S)—S—S—C(S)—N<), Sulfinylamines (—N=SO), Sulfonylamines (—N=SO2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4866—Organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Surgery (AREA)
  • Virology (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
JP2004111761A 2003-04-08 2004-04-06 固形医薬組成物 Expired - Lifetime JP5495467B2 (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46121503P 2003-04-08 2003-04-08
US60/461215 2003-04-08

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2010188835A Division JP5543298B2 (ja) 2003-04-08 2010-08-25 固形医薬組成物

Publications (3)

Publication Number Publication Date
JP2004307506A JP2004307506A (ja) 2004-11-04
JP2004307506A5 JP2004307506A5 (OSRAM) 2010-10-14
JP5495467B2 true JP5495467B2 (ja) 2014-05-21

Family

ID=32326722

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004111761A Expired - Lifetime JP5495467B2 (ja) 2003-04-08 2004-04-06 固形医薬組成物
JP2010188835A Expired - Lifetime JP5543298B2 (ja) 2003-04-08 2010-08-25 固形医薬組成物
JP2013090602A Pending JP2013177404A (ja) 2003-04-08 2013-04-23 固形医薬組成物

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2010188835A Expired - Lifetime JP5543298B2 (ja) 2003-04-08 2010-08-25 固形医薬組成物
JP2013090602A Pending JP2013177404A (ja) 2003-04-08 2013-04-23 固形医薬組成物

Country Status (41)

Country Link
US (11) US20060275357A1 (OSRAM)
EP (5) EP2008650A3 (OSRAM)
JP (3) JP5495467B2 (OSRAM)
KR (3) KR20050121712A (OSRAM)
CN (2) CN101797241B (OSRAM)
AR (3) AR043987A1 (OSRAM)
AT (3) ATE414508T1 (OSRAM)
AU (1) AU2004228929B2 (OSRAM)
BE (2) BE1015972A5 (OSRAM)
BR (1) BRPI0409250B8 (OSRAM)
CA (2) CA2521325C (OSRAM)
CL (2) CL2004000745A1 (OSRAM)
CY (3) CY1110260T1 (OSRAM)
DE (4) DE122011100047I1 (OSRAM)
DK (2) DK2316431T3 (OSRAM)
EC (1) ECSP056090A (OSRAM)
ES (3) ES2556947T3 (OSRAM)
FR (2) FR2854073B1 (OSRAM)
GB (1) GB2400318B (OSRAM)
GR (1) GR1005052B (OSRAM)
HR (3) HRP20100601B1 (OSRAM)
HU (2) HUE028247T2 (OSRAM)
IL (3) IL170888A (OSRAM)
IS (2) IS2682B (OSRAM)
IT (1) ITMI20040682A1 (OSRAM)
LU (1) LU91867I2 (OSRAM)
MA (1) MA27729A1 (OSRAM)
MX (1) MXPA05010860A (OSRAM)
MY (1) MY141249A (OSRAM)
NO (4) NO329332B1 (OSRAM)
NZ (3) NZ542622A (OSRAM)
PE (5) PE20150676A1 (OSRAM)
PL (2) PL1613288T3 (OSRAM)
PT (1) PT1613288E (OSRAM)
RU (5) RU2358716C2 (OSRAM)
SG (1) SG175449A1 (OSRAM)
SI (2) SI2316431T1 (OSRAM)
TN (1) TNSN05256A1 (OSRAM)
TW (1) TWI332847B (OSRAM)
WO (1) WO2004089341A1 (OSRAM)
ZA (1) ZA200507394B (OSRAM)

Families Citing this family (72)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1993115B (zh) * 2004-07-30 2011-12-28 诺瓦提斯公司 2-氨基-1,3-丙二醇化合物的制剂
CN1891212B (zh) * 2005-07-07 2010-10-13 马启明 一种口服制剂及其制备方法
MX2008003170A (es) * 2005-09-09 2008-03-18 Novartis Ag Tratamiento de enfermedades autoinmunes.
KR101434522B1 (ko) 2005-11-09 2014-08-26 오닉스 세라퓨틱스, 인크. 효소 저해를 위한 화합물
TWI389683B (zh) * 2006-02-06 2013-03-21 Kyorin Seiyaku Kk A therapeutic agent for an inflammatory bowel disease or an inflammatory bowel disease treatment using a 2-amino-1,3-propanediol derivative as an active ingredient
RU2450016C2 (ru) 2006-06-19 2012-05-10 Протеоликс, Инк. Пептидные эпоксикетоны для ингибирования протеасомы
GB0612721D0 (en) 2006-06-27 2006-08-09 Novartis Ag Organic compounds
KR102044064B1 (ko) * 2006-09-26 2019-11-12 노파르티스 아게 Ｓ１ｐ 조정제를 포함하는 제약 조성물
EP1923058A1 (en) * 2006-09-26 2008-05-21 Novartis AG Coated pharmaceutical composition comprising an S1P agonist or modulator
AU2011235934A1 (en) * 2006-09-26 2011-11-03 Novartis Ag Pharmaceutical compositions comprising an S1P modulator
EP1905434A1 (en) * 2006-09-26 2008-04-02 Novartis AG Organic compounds comprising an S1P receptor agonist and their therapeutic use
EP1923054A1 (en) * 2006-09-26 2008-05-21 Novartis AG Fast disintegrating pharmaceutical composition comprising an S1P agonist or modulator
EP1923055A1 (en) * 2006-09-26 2008-05-21 Novartis AG Freeze-dried pharmaceutical composition comprising an S1P agonist or modulator
WO2008124210A1 (en) * 2007-02-14 2008-10-16 Emory University Methods and compositions for treating or preventing infection using leukocyte sequestration agents
NZ597109A (en) 2007-03-29 2013-01-25 Daiichi Sankyo Co Ltd Tablet composition having favorable dissolution property useful as an anticoagulant
SI2207791T2 (sl) 2007-10-04 2019-09-30 Onyx Therapeutics, Inc. Kristalinični peptidepoksiketonski proteazni inhibitorji in sinteza aminokislinskih ketoepoksidov
AU2012216630B2 (en) * 2007-10-12 2015-01-22 Novartis Ag Compositions comprising sphingosine 1 phosphate (S1P) receptor modulators
JOP20080436B1 (ar) * 2007-10-12 2023-03-28 Novartis Ag تركيبات تشتمل على معدلات مستقبل سفينجوزين 1 فوسفات (s1p)
JP5534645B2 (ja) * 2008-01-11 2014-07-02 日医工株式会社 無包装状態において安定性に優れた塩酸サルポグレラート含有経口投与製剤
WO2009099174A1 (ja) 2008-02-07 2009-08-13 Kyorin Pharmaceutical Co., Ltd. アミノアルコール誘導体を有効成分とする炎症性腸疾患の治療剤又は予防剤
AR070842A1 (es) 2008-03-17 2010-05-05 Actelion Pharmaceuticals Ltd Regimen de dosificacion para un agonista de receptor selectivo de s1p1
EP2303250A1 (en) 2008-06-20 2011-04-06 Novartis AG Paediatric compositions for treating1 multiple sclerosis
KR101647855B1 (ko) * 2008-06-20 2016-08-11 메르크 파텐트 게엠베하 직접 사출성형가능한 신속 붕해 정제 매트릭스
EP2334202B1 (en) * 2008-09-04 2012-02-01 Cargill, Incorporated Tabletting of ervthritol
EP2796134B1 (en) 2008-10-21 2016-12-07 Onyx Therapeutics, Inc. Combination of the peptide epoxyketone proteasome inhibitor carfilzomib with melphalan for use in the treatment of multiple myeloma
AU2013100531B4 (en) * 2008-11-11 2013-11-28 Novartis Ag Crystalline forms of fingolimod HCL
EP2358660A2 (en) 2008-11-11 2011-08-24 Novartis AG Salts of fingolimod
KR20130109254A (ko) * 2008-11-11 2013-10-07 노파르티스 아게 핑골리모드 ｈｃｌ의 결정질 형태
JP5305421B2 (ja) 2008-12-17 2013-10-02 第一三共株式会社 ジアミン誘導体の製造方法
JPWO2010082531A1 (ja) 2009-01-13 2012-07-05 第一三共株式会社 活性化血液凝固因子阻害剤
ES2542236T3 (es) 2009-03-10 2015-08-03 Daiichi Sankyo Company, Limited Procedimiento de producción de un derivado de diamina
JP5652879B2 (ja) 2009-03-13 2015-01-14 第一三共株式会社 光学活性なジアミン誘導体の製造方法
AR075899A1 (es) 2009-03-20 2011-05-04 Onyx Therapeutics Inc Tripeptidos epoxicetonas cristalinos inhibidores de proteasa
CA2765522A1 (en) * 2009-06-18 2010-12-23 Daiichi Sankyo Company, Limited Solid pharmaceutical composition of edoxaban having improved solubility
US9675566B2 (en) 2009-07-16 2017-06-13 Pathologica Llc Method of treatment with anti-inflammatory and analgesic compounds which are GI-, renal-, and platelet-sparing
EP2498793B1 (en) 2009-11-13 2019-07-10 Onyx Therapeutics, Inc. Oprozomib for use in metastasis suppression
AU2011223795B2 (en) 2010-03-01 2015-11-05 Onyx Therapeutics, Inc. Compounds for immunoproteasome inhibition
EP2548879B1 (en) 2010-03-19 2015-12-09 Daiichi Sankyo Company, Limited Crystal of diamine derivative and method of producing same
EP2548556B1 (en) 2010-03-19 2016-08-10 Daiichi Sankyo Company, Limited Method for improving dissolvability of anticoagulant
WO2011131368A2 (en) * 2010-04-22 2011-10-27 Ratiopharm Gmbh A method of preparing an oral dosage form comprising fingolimod
KR101795096B1 (ko) 2010-07-02 2017-12-01 다이이찌 산쿄 가부시키가이샤 광학 활성 디아민 유도체의 염의 제조 방법
US9266816B2 (en) 2010-11-25 2016-02-23 Shilpa Medicare Limited Fingolimod polymorphs and their processes
UA114283C2 (uk) 2011-01-07 2017-05-25 Новартіс Аг Композиції імуносупресантів
NO2665471T3 (OSRAM) 2011-01-19 2018-05-26
JO3177B1 (ar) 2011-04-01 2018-03-08 Novartis Ag تركيبات تتالف من 2-أمينو-2- [ 2- ( 4- أكتيل فينيل ) إثيل ] بروبان - 3, 1- ديول
US9186333B2 (en) * 2011-08-01 2015-11-17 Teva Pharmaceutical Industries Ltd. Process for preparing pharmaceutical compositions of fingolimod
CA2844604C (en) 2011-08-10 2017-07-18 Daiichi Sankyo Company, Limited Pharmaceutical composition containing ethanediamide derivatives
WO2013091704A1 (en) 2011-12-22 2013-06-27 Synthon Bv Pharmaceutical composition comprising fingolimod
RU2482842C1 (ru) * 2012-04-26 2013-05-27 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний (варианты) и способ ее получения
RU2506949C1 (ru) * 2012-06-13 2014-02-20 Открытое акционерное общество "Новосибхимфарм" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
US20140105921A1 (en) 2012-07-09 2014-04-17 Onyx Therapeutics, Inc. Prodrugs of Peptide Epoxy Ketone Protease Inhibitors
RU2496486C1 (ru) * 2012-07-11 2013-10-27 Александр Васильевич Иващенко Фармацевтическая композиция с улучшенной сыпучестью, лекарственное средство, способ получения и применение
EP2943189B1 (en) * 2013-01-08 2021-03-10 Pathologica LLC Mitoguazone for treatment of progressive multiple sclerosis
WO2014141298A2 (en) * 2013-03-11 2014-09-18 Astron Research Limited Stable pharmaceutical composition of fingolimod
EP2990055B1 (en) * 2013-04-26 2019-06-05 Kyoto University Composition comprising a sphingosine-1-phosphate receptor 1 agonist for inhibiting formation and/or enlargement of cerebral aneurysm or for shrinking it
ES2770500T3 (es) * 2013-05-13 2020-07-01 Synthon Bv Composición farmacéutica que comprende fingolimod
EP3027174B1 (en) 2013-07-29 2019-07-24 Aizant Drug Research Solutions Private Limited Pharmaceutical compositions of fingolimod
RU2530626C1 (ru) * 2013-10-21 2014-10-10 Ооо "Валента-Интеллект" Фармацевтическая композиция агониста рецептора s1p для лечения демиелинизационных заболеваний
WO2016026461A1 (en) * 2014-08-22 2016-02-25 Sunshine Lake Pharma Co., Ltd. Solid composition of fingolimod and preparation thereof
WO2016042493A1 (en) * 2014-09-19 2016-03-24 Aizant Drug Research Pvt. Ltd Pharmaceutical compositions of fingolimod
US9925138B2 (en) 2015-01-20 2018-03-27 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
AU2016209466A1 (en) * 2015-01-20 2017-08-10 Handa Pharmaceuticals, Llc Stable solid fingolimod dosage forms
WO2016135644A1 (en) 2015-02-26 2016-09-01 Novartis Ag Treatment of autoimmune disease in a patient receiving additionally a beta-blocker
RU2577230C1 (ru) * 2015-04-09 2016-03-10 Общество с ограниченной ответственностью "Лонг Шенг Фарма Рус" Способ получения капсул финголимода гидрохлорида
US9690975B2 (en) 2015-05-28 2017-06-27 Axogen Corporation Quantitative structural assay of a nerve graft
US11434200B2 (en) 2017-03-09 2022-09-06 Novartis Ag Solid forms comprising an oxime ether compound and a coformer, compositions and methods of use thereof
WO2018178744A1 (en) 2017-03-29 2018-10-04 Deva Holding Anonim Sirketi Stable formulations of fingolimod
GR1009654B (el) 2018-08-31 2019-11-18 Φαρματεν Α.Β.Ε.Ε. Φαρμακευτικο σκευασμα που περιλαμβανει εναν ανοσοτροποποιητικο παραγοντα και μεθοδος για την παρασκευη αυτου
DE102018217334A1 (de) * 2018-10-10 2020-04-16 Harbins Ruhr Bioscience, Inc. Sphingoid-Base und/oder Wirkstoff zur Verwendung bei der Prophylaxe und/oder Therapie einer viralen Infektion und/oder viralen Infektionskrankheit oder der Desinfektion, Nahrungsmittel/Nahrungsergänzungsmittel, Futtermittel/Futterergänzungsmittel und Pflanzenschutzmittel
JP7503420B2 (ja) * 2020-05-18 2024-06-20 東和薬品株式会社 フィンゴリモドを含む医薬組成物とその製造方法及び安定化方法
WO2022015348A1 (en) 2020-07-16 2022-01-20 Harbins Ruhr Bioscience, Inc. Sphingoid compounds for use in prophylaxis and/or therapy of coronaviridae infection
WO2022162088A2 (en) * 2021-01-28 2022-08-04 Priothera Sas Methods of treatment with s1p receptor modulators

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL7607683A (nl) * 1976-07-12 1978-01-16 Akzo Nv Werkwijze ter bereiding van nieuwe peptiden en peptide-derivaten en de toepassing hiervan.
US4110332A (en) * 1977-05-05 1978-08-29 Chevron Research Company 1-Triorganostannyl-3-organothio-4-substituted-1,2,4-delta2 -triazolidin-5-ones
US4559153A (en) 1983-10-25 1985-12-17 Phillips Petroleum Company Metal working lubricant
US5112616A (en) * 1988-11-30 1992-05-12 Schering Corporation Fast dissolving buccal tablet
JP2841857B2 (ja) * 1990-11-29 1998-12-24 田辺製薬株式会社 長期間安定な経口用医薬製剤
US5604229A (en) 1992-10-21 1997-02-18 Yoshitomi Pharmaceutical Industries, Ltd. 2-amino-1,3-propanediol compound and immunosuppressant
EP0778263B1 (en) 1994-08-22 2002-01-09 Welfide Corporation Benzene compound and medicinal use thereof
SK282225B6 (sk) 1995-12-28 2001-12-03 Welfide Corporation Použitie 2-amino-2[2-(4-oktylfenyl)etyl]-propán-1,3-diolu alebo jeho farmaceuticky prijateľnej adičnej soli s kyselinou na výrobu farmaceutického prostriedku
JP2002241272A (ja) * 1996-07-18 2002-08-28 Mitsubishi Pharma Corp 医薬処方組成物
JPH11209277A (ja) * 1998-01-19 1999-08-03 Yoshitomi Pharmaceut Ind Ltd 医薬組成物
US6476004B1 (en) * 1996-07-18 2002-11-05 Mitsubishi Pharma Corporation Pharmaceutical composition
GB9624038D0 (en) 1996-11-19 1997-01-08 Sandoz Ltd Organic compounds
SI0990440T1 (sl) * 1997-02-27 2009-04-30 Novartis Ag Farmacevtski sestavek, ki obsega 2-amino-2-(2-(4-oktilfenil)etil)propan-1,3-diol, lecitin in saharid
SI1319651T1 (en) * 1997-04-04 2005-10-31 Mitsubishi Pharma Corporation 2-Aminopropane-1,3-diol compound, pharmaceutical use thereof and synthetic intermediates therefor
JPH1180026A (ja) * 1997-09-02 1999-03-23 Yoshitomi Pharmaceut Ind Ltd 新規免疫抑制剤、その使用方法およびその同定方法
JP3545595B2 (ja) 1998-04-01 2004-07-21 花王株式会社 スフィンゴ糖脂質の製造法
JP4627356B2 (ja) * 1999-06-30 2011-02-09 昭 松森 ウイルス性心筋炎の予防または治療薬剤
WO2001003739A1 (fr) * 1999-07-12 2001-01-18 Ono Pharmaceutical Co., Ltd. Inhibiteurs de fibrose contenant comme ingredient actif l'agoniste du recepteur de sphingosine-1-phosphate ou la sphingosine-1-phosphate
SK152003A3 (en) 2000-07-13 2004-07-07 Sankyo Co Amino alcohol derivatives
WO2002018395A1 (en) * 2000-08-31 2002-03-07 Merck & Co., Inc. Phosphate derivatives as immunoregulatory agents
US6953332B1 (en) 2000-11-28 2005-10-11 St. Jude Medical, Inc. Mandrel for use in forming valved prostheses having polymer leaflets by dip coating
IL157773A0 (en) 2001-03-26 2004-03-28 Novartis Ag 2-amino-propanol derivatives
US7521192B2 (en) 2001-04-18 2009-04-21 Rigel Pharmaceuticals, Inc. EDG: modulators of lymphocyte activation and migration
JP2002316985A (ja) 2001-04-20 2002-10-31 Sankyo Co Ltd ベンゾチオフェン誘導体
US20040235794A1 (en) 2001-09-04 2004-11-25 Shinji Nakade Remedies for respiratory diseases comprising sphingosine-1-phosphate receptor controller
WO2003029184A1 (en) 2001-09-27 2003-04-10 Kyorin Pharmaceutical Co., Ltd. Diaryl ether derivative, addition salt thereof, and immunosuppressant
CN1329372C (zh) 2001-09-27 2007-08-01 杏林制药株式会社 二芳基硫醚衍生物及其加成盐和免疫抑制剂
WO2003062252A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Edg receptor agonists
WO2003062248A2 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
CA2473740A1 (en) 2002-01-18 2003-07-31 David Solow-Cordero Methods of treating conditions associated with an edg receptor
CA2472680A1 (en) 2002-01-18 2003-07-31 Merck & Co., Inc. Selective s1p1/edg1 receptor agonists
PT1772145E (pt) * 2004-07-16 2011-05-27 Kyorin Seiyaku Kk Processo de utiliza??o eficaz de um medicamento e processo respeitante ? preven??o de efeitos secund?rios

Also Published As

Publication number Publication date
HRP20100600A2 (hr) 2011-03-31
PT1613288E (pt) 2009-02-25
PE20090743A1 (es) 2009-07-17
EP2316431B1 (en) 2015-09-30
EP2769713A1 (en) 2014-08-27
FR2854073B1 (fr) 2008-03-14
CA2521325A1 (en) 2004-10-21
KR101367574B1 (ko) 2014-02-25
ATE414508T1 (de) 2008-12-15
US8324283B2 (en) 2012-12-04
LU91867I9 (OSRAM) 2019-01-03
IS8885A (is) 2010-02-25
NZ586280A (en) 2011-12-22
US20190175527A1 (en) 2019-06-13
NO335120B1 (no) 2014-09-22
GR20040100121A (el) 2004-12-17
CY1110260T1 (el) 2014-04-09
CN1767819B (zh) 2010-07-28
RU2012148593A (ru) 2014-05-20
NZ592339A (en) 2012-09-28
EP2316431A1 (en) 2011-05-04
HK1071685A1 (en) 2005-07-29
EP1613288B1 (en) 2008-11-19
JP2004307506A (ja) 2004-11-04
NO20131287L (no) 2006-01-09
ES2556947T3 (es) 2016-01-21
HRP20100601A2 (hr) 2011-03-31
ES2228282B1 (es) 2006-02-16
FR11C0036I1 (fr) 2011-10-14
CY1117071T1 (el) 2017-04-05
CN101797241B (zh) 2013-03-27
NO20055231D0 (no) 2005-11-07
DE102004016947A1 (de) 2004-10-21
US20170290787A1 (en) 2017-10-12
ES2320767T3 (es) 2009-05-28
IL197578A0 (en) 2011-07-31
HK1155647A1 (en) 2012-05-25
JP5543298B2 (ja) 2014-07-09
KR20050121712A (ko) 2005-12-27
SI2316431T1 (sl) 2016-04-29
EP2319502A1 (en) 2011-05-11
RU2009105403A (ru) 2010-08-27
EP2008650A3 (en) 2011-04-27
US20220031609A1 (en) 2022-02-03
SI1613288T1 (sl) 2009-04-30
AT504853A2 (de) 2008-08-15
ES2228282A1 (es) 2005-04-01
US20130108675A1 (en) 2013-05-02
HUS1100016I1 (hu) 2016-08-29
NO334116B1 (no) 2013-12-16
PE20131352A1 (es) 2013-11-14
IS8114A (is) 2005-11-01
CN1767819A (zh) 2006-05-03
BRPI0409250B8 (pt) 2022-01-18
GB0407819D0 (en) 2004-05-12
IL197578A (en) 2015-10-29
CN101797241A (zh) 2010-08-11
RU2475236C2 (ru) 2013-02-20
US20060275357A1 (en) 2006-12-07
PE20130200A1 (es) 2013-03-09
CA2707750A1 (en) 2004-10-21
FR11C0036I2 (fr) 2023-12-29
ECSP056090A (es) 2006-03-01
RU2005134173A (ru) 2006-09-10
KR20110005320A (ko) 2011-01-17
NO20055231L (no) 2006-01-09
PL2316431T3 (pl) 2016-09-30
EP2008650A2 (en) 2008-12-31
HRP20050886B1 (en) 2011-01-31
US20140011885A1 (en) 2014-01-09
LU91867I2 (fr) 2011-11-08
IL170888A (en) 2010-06-16
AR043987A1 (es) 2005-08-17
SG175449A1 (en) 2011-11-28
BE2011C030I2 (OSRAM) 2023-03-07
AT501681B1 (de) 2012-04-15
RU2475237C2 (ru) 2013-02-20
ITMI20040682A1 (it) 2004-07-06
JP2013177404A (ja) 2013-09-09
TNSN05256A1 (en) 2007-07-10
DE602004017847D1 (de) 2009-01-02
CY2011013I1 (el) 2014-04-09
RU2010147000A (ru) 2012-08-10
DK1613288T3 (da) 2009-03-23
IL242037A0 (en) 2015-11-30
AT501681A1 (de) 2006-10-15
MA27729A1 (fr) 2006-01-02
GB2400318B (en) 2005-08-10
HUE028247T2 (en) 2016-12-28
PE20050396A1 (es) 2005-07-05
CA2521325C (en) 2010-09-14
DE202004021680U1 (de) 2010-04-22
NO2011016I1 (no) 2011-09-19
NO329332B1 (no) 2010-09-27
ZA200507394B (en) 2007-03-28
BRPI0409250A (pt) 2006-03-28
MXPA05010860A (es) 2006-05-25
US20200237690A1 (en) 2020-07-30
RU2358716C2 (ru) 2009-06-20
US20080311188A1 (en) 2008-12-18
MY141249A (en) 2010-03-31
DE122011100047I1 (de) 2011-12-15
NO20100250L (no) 2006-01-09
US20110105620A1 (en) 2011-05-05
WO2004089341A1 (en) 2004-10-21
HRP20100601B1 (hr) 2016-12-02
PL1613288T3 (pl) 2009-07-31
IS2682B (is) 2010-10-15
US20140255497A1 (en) 2014-09-11
DK2316431T3 (en) 2016-01-11
NO2011016I2 (no) 2012-08-27
KR20120101148A (ko) 2012-09-12
TW200503784A (en) 2005-02-01
PE20150676A1 (es) 2015-05-17
AR078782A2 (es) 2011-11-30
IE20040246A1 (en) 2004-12-15
NZ542622A (en) 2009-01-31
HK1091114A1 (en) 2007-01-12
EP1613288A1 (en) 2006-01-11
GR1005052B (el) 2005-11-30
AU2004228929B2 (en) 2008-02-07
FR2854073A1 (fr) 2004-10-29
CY2011013I2 (el) 2014-04-09
TWI332847B (en) 2010-11-11
US20090203798A1 (en) 2009-08-13
RU2010146697A (ru) 2012-05-27
AU2004228929A1 (en) 2004-10-21
BRPI0409250B1 (pt) 2017-07-11
CL2004000745A1 (es) 2005-02-11
GB2400318A (en) 2004-10-13
BE1015972A5 (fr) 2005-12-06
CL2011000450A1 (es) 2011-11-25
AR078781A2 (es) 2011-11-30
JP2011006461A (ja) 2011-01-13
HRP20050886A2 (en) 2006-11-30

Similar Documents

Publication Publication Date Title
JP5495467B2 (ja) 固形医薬組成物
IE85095B1 (en) Pharmaceutical composition comprising a sphingosine-1 phosphate receptor agonist
HK1091114B (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
HK1155650A (en) Solid pharmaceutical compositions comprising a s1p receptor agonist and a sugar alcohol
AU2008200368A1 (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol
AU2011205050A1 (en) Solid pharmaceutical compositions comprising a S1P receptor agonist and a sugar alcohol

Legal Events

Date Code Title Description
RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20041020

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20041020

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20070326

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20070427

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A712

Effective date: 20071102

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100525

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20100825

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20100928

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20110317

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130828

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130909

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20131031

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20131106

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20131203

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20131203

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20140304

R150 Certificate of patent or registration of utility model

Ref document number: 5495467

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S531 Written request for registration of change of domicile

Free format text: JAPANESE INTERMEDIATE CODE: R313531

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term